Soligenix reports Q2 EPS ($1.31) vs ($3.56) last year

Reports Q2 revenue less than $0.1M vs $0.2M last year. “This is a pivotal time for Soligenix with a great deal of clinical activity and upcoming milestones,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “While we prepare for the upcoming initiation of our confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte(TM) (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease, we are incredibly encouraged by the recent positive clinical results from our comparability study evaluating HyBryte(TM) against Valchlor(R) (mechlorethamine gel), which demonstrated a three-fold higher response rate over a 12-week treatment period and more favorable safety profile for HyBryte(TM) in the treatment of CTCL. These findings, coupled with the promising interim data from the ongoing open-label, investigator-initiated study evaluating extended HyBryte(TM) treatment, reinforce our excitement about the future of HyBryte(TM) as a potential front-line treatment option for patients with early-stage CTCL. Additionally, we will be initiating a Phase 2 study with SGX945 (dusquetide) in Behcet’s disease later this year with top-line results expected in the first half of 2025, along with top-line results expected during the same timeframe from our ongoing SGX302 (synthetic hypericin) Phase 2 study in mild-to-moderate psoriasis.”